Pituitary apoplexy associated with cabergoline therapy

J Clin Neurosci. 2013 Dec;20(12):1637-43. doi: 10.1016/j.jocn.2013.02.027. Epub 2013 Oct 7.

Abstract

Pituitary apoplexy is a rare medical emergency which results from hemorrhage or infarction in the pituitary gland. One of the predisposing factors is treatment with dopamine agonists, especially bromocriptine. We report a 20-year-old Chinese man with prolactinoma who developed pituitary apoplexy 6 weeks after initiation of cabergoline. He was treated conservatively with supportive therapy, and recovered well with no loss of pituitary function. A literature search was conducted and a review of the reported patients with pituitary apoplexy during treatment with dopamine agonists is discussed.

Keywords: Bromocriptine; Cabergoline; Dopamine agonist; Pituitary apoplexy; Prolactinoma.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Cabergoline
  • Dopamine Agonists / adverse effects*
  • Dopamine Agonists / therapeutic use
  • Ergolines / adverse effects*
  • Ergolines / therapeutic use
  • Humans
  • Male
  • Pituitary Apoplexy / chemically induced*
  • Pituitary Apoplexy / pathology
  • Pituitary Neoplasms / drug therapy
  • Pituitary Neoplasms / pathology
  • Prolactinoma / drug therapy
  • Prolactinoma / pathology
  • Young Adult

Substances

  • Antineoplastic Agents
  • Dopamine Agonists
  • Ergolines
  • Cabergoline